Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) updated its FY 2026 earnings guidance on Thursday. Halozyme Therapeutics Price PerformanceShares of Halozyme Therapeutics stock opened at $103.12 on Friday. Get Halozyme Therapeutics alerts:Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Read MoreReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.